assessing efgr tkis in patients with wild-type efgr nsclc
Published 2 years ago • 84 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
1:18
exploring neoadjuvant egfr-tkis in lung cancer
-
1:33
neoadjuvant egfr tki trials in nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
1:04
molecular testing in egfr mutant driven nsclc
-
1:05
advances in managing krasg12c- and egfr-mutated nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
4:37
advances in efgr-mutant nsclc treatment
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
1:41
egfr mutations in patients with lung cancer
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
2:41
egfr tkis in the adjuvant setting in nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
2:47
etop clinical trials in egfr-, krasg12c- and alk-mutated nsclc
-
12:58
egfr inhibitor therapy in second line
-
2:05
assess trial: blood test for egfr mutation in advanced non-small cell lung cancer
-
2:10
dr. pennell on importance of egfr testing in nsclc